Clinical Trial Update: Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial investigating a JAK-STAT pathway inhibitor for APOL1-associated kidney disease has completed (sponsor: Duke University).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apol1-associated Kidney Disease
• Chronic Kidney Disease

Snippet

Sponsor: Duke University | Conditions: Chronic Kidney Diseases | Phase 2 | Status: COMPLETED